DiviTum™ selected for a new, state of the art, breast cancer study at Karolinska Institutet and University Hospital

Biovicas technology for measuring cell proliferation, DiviTum™, has been selected for inclusion in a new study of women with breast cancer at Karolinska Institutet and Radiumhemmet.
The study, PREDIX LumA, aims to include 200 women with hormone-dependent breast cancer that will be treated with endocrine treatment in combination with a new targeted drug (a so called CDK-inhibitor), developed to stop proliferation in tumor cells. DiviTum™ will be used to analyse the cell proliferation rate in blood taken from patients before and during therapy. The main purposes are to predict which patients have the best conditions to respond but also to evaluate efficacy during treatment.


Thomas Hatschek

“We have chosen to include DiviTum in the study to see if we can use it as a non-invasive marker of efficacy for this new class of drugs called CDK4/6-inhibitors. This is a very promising group of new drugs but we lack a reliable marker of tumor proliferation to evaluate and predict efficacy. There is a reasonable potential and scientific rationale that DiviTum may correlate with the efficacy of these new drugs”, says Thomas Hatschek, lead investigator for the study and Associate Professor at Karolinska Institutet.


“We are excited that DiviTum has been selected for this highly relevant study. We look forward to continued collaboration with Karolinska Institutet, contributing to improved diagnostics and monitoring of breast cancer patients”, says Anders Rylander, CEO Biovica.


Facts about Biovica and DiviTum™

Biovica is a bio-diagnostic company focused on improving diagnostics, providing better predicitve data and monitoring of patients with cancer. Biovica has developed a blood test, DiviTum™, a highly sensitive assay for measuring cell proliferation. Since one of the most fundamental characteristics of cancer is uncontrolled and increased cell growth, DiviTum™ enables reliable prediction and therapy monitoring of cancer with an unprecedented sensitivity and precision. Biovica is ISO 13485 certified for Quality Management Systems and DiviTum™ is CE labelled and MPA registered.

For more information:

Thomas Hatschek, Associate Professor at Radiumhemmet, Karolinska University Hospital, the Karolinska Institute, Department of Oncology-pathology.
Lead Investigator in the PREDIX-study.Mobile phone: + 46 (0) 709 24 43 41
e-mail: thomas.hatschek@karolinska.se

Anders Rylander, CEO Biovica.

Mobile phone: +46 (0) 761 61 21 90
e-mail: anders.rylander@biovica.com

2015-01-27T08:00:04+00:00 January 27th, 2015 08:00|Regulatory|